120 patents
Page 4 of 6
Utility
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
26 Apr 22
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob Dale Brown, Henryk T. Dudek
Filed: 12 Aug 21
Utility
Methods and compositions for inhibiting expression of LDHA
29 Mar 22
This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
Filed: 12 Oct 18
Utility
Methods for treating hepatitis B infection
15 Mar 22
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin Koser, Marc Abrams
Filed: 12 May 21
Utility
Compositions and Methods for Inhibiting HMGB1 Expression
10 Mar 22
This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes.
Marc ABRAMS, Girish CHOPDA, Uihye PARK
Filed: 20 Dec 19
Utility
Double-stranded Nucleic Acid Inhibitor Molecules Containing a Triloop
3 Mar 22
Provided herein are double-stranded nucleic acid inhibitor molecules having a sense strand with a stem loop structure and an antisense strand, where the loop portion of the stem loop structure is a triloop.
Bob Dale BROWN
Filed: 13 Nov 19
Utility
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
30 Dec 21
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 20 Aug 21
Utility
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
28 Dec 21
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 1 Jul 20
Utility
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
16 Dec 21
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 20 Aug 21
Utility
Compositions and Methods for Inhibiting ALDH2 Expression
9 Dec 21
This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes.
Utsav SAXENA
Filed: 15 Jan 19
Utility
Amine Cationic Lipids and Uses Thereof
23 Sep 21
The present invention relates to lipid compounds and uses thereof.
Bob Dale Brown
Filed: 8 Jun 21
Utility
Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression
23 Sep 21
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 4 Jun 21
Utility
Methods for Treating Hepatitis B Infection
16 Sep 21
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin KOSER, Marc ABRAMS
Filed: 12 May 21
Utility
Beta Catenin Nucleic Acid Inhibitor Molecule
5 Aug 21
Provided herein is a potent, optimized β-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides.
Shanthi GANESH
Filed: 15 Apr 21
Utility
PCSK9 Targeting Oligonucleotides for Treating Hypercholesterolemia and Related Conditions
5 Aug 21
This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes.
Henryk T. DUDEK, Jihye PARK
Filed: 1 Apr 19
Utility
Methods and Compositions for the Specific Inhibition of Glycolate Oxidase (HAO1) by Double-stranded Rna
29 Jul 21
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. BROWN, Henryk T. DUDEK
Filed: 25 Jan 21
Utility
Methods and compositions for the specific inhibition of transthyretin (TTR) by double stranded RNA
20 Jul 21
This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 1 Apr 20
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
13 Jul 21
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 20 Aug 19
Utility
Amine cationic lipids and uses thereof
13 Jul 21
The present invention relates to lipid compounds and uses thereof.
Bob Dale Brown
Filed: 29 Nov 18
Utility
Methods for treating hepatitis B infection
6 Jul 21
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin Koser, Marc Abrams
Filed: 7 Jul 20
Utility
Methods for treating hepatitis B infection
6 Jul 21
This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.
Martin Koser, Marc Abrams
Filed: 7 Jul 20